ADIL - Adial Pharmaceuticals, Inc.
4.00 -0.20 (-4.76%)
After hours: 7:39PM EST
| Previous Close | 4.3000 |
| Open | 4.3600 |
| Bid | 4.00 x 800 |
| Ask | 4.58 x 1200 |
| Day's Range | 3.9410 - 4.3600 |
| 52 Week Range | 1.1100 - 9.4400 |
| Volume | 452,120 |
| Avg. Volume | 1,799,160 |
| Market Cap | 29.242M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.75 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- GlobeNewswire•14 hours ago
Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has submitted a continuation patent application with U.S. Patent and Trademark Office to broaden the claims relating to the use of AD04 for opioid dependence and abuse, commonly referred to as Opioid Use Disorder (OUD). William Stilley, CEO of Adial Pharmaceuticals, stated, “Given the progress we are making advancing towards our Phase 3 trial for AD04 in Alcohol Use Disorder (AUD), we are now accelerating our efforts to expand into other indications.
- GlobeNewswire•4 days ago
Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
ADILW) http://www.adialpharma.com/, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has appointed Professor Markus Heilig, MD, PhD as a Scientific Advisory Board (SAB) member. The SAB is charged with helping to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
- GlobeNewswire•9 days ago
Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award
The award recognizes and honors an individual who has made highly meritorious contributions in advancing the scientific understanding of alcoholism, its prevention and treatment. The Award and lecture will be presented at ASAM’s 50th Annual Conference in April, 2019.
- GlobeNewswire•15 days ago
Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that William Stilley, President and Chief Executive Officer, will appear today on the KSWB-TV FOX 5 Morning News in San Diego at 10:40 AM ET/7:40 AM PT. Additionally, he is scheduled to appear on the KPIX-TV (CBS-CW) “Bay Area Focus” morning show on February 3 during the 2:00 PM ET/11:00 AM PT hour.
- GlobeNewswire•23 days ago
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has received $1.2 million in capital through the voluntary exercise of previously outstanding warrants to purchase 243,100 shares of its common stock. Additionally, 125,000 shares were issued as part of the cashless exercise of warrants. “We remain focused on the operations and milestones related to our Phase 3 clinical trial of AD04 for Alcohol Use Disorder and AD04’s initial development for Opioid Use Disorder.
- Simply Wall St.•23 days ago
What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)?
If you want to know who really controls Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...
- GlobeNewswire•last month
Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has appointed Professor Tomáš Zima, MD, DSc, Dr.h.c. Doctors Zima and Mueller bring broad and diversified experience in areas such as addiction, genetics and the diagnosis and treatment of alcohol related diseases. The SAB is charged with helping to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
- GlobeNewswire•last month
Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series
Adial Pharmaceuticals, Inc. (ADIL), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole Johnson, MD, the Company’s Chairman of the Board, was featured in a second video produced by The Doctors Channel discussing the Company’s lead asset AD04 alcohol use disorder (AUD) drug about to begin Phase 3 clinical trials. The Doctors Channel is the world’s largest video site for doctors featuring short-form accredited CME, medical news and lifestyle videos. Dr. Johnson is a renowned addiction expert and currently holds a number of titles including the Dr. Irving J. Taylor Professor and Chair, Department of Psychiatry, University of Maryland.
- GlobeNewswire•last month
Adial Pharmaceuticals to Present at The 2019 Wall Street Conference
CHARLOTTESVILLE, Va., Jan. 10, 2019 -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the.
- ACCESSWIRE•2 months ago
These 4 Healthcare Stocks Are Gaining Speed
CORAL GABLES, FL / ACCESSWIRE / December 27, 2018 / With the new year less than one week away, the healthcare industry is effervescent with excitement as companies work towards designing new methods and technologies to dramatically improve care options available to consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI), BioXcel Therapeutics Inc (BTAI), Axsome Therapeutics Inc (AXSM), and Adial Pharmaceuticals are 4 healthcare stocks representing companies dead-set on fostering the best possible care options and products in their sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company you may not have heard of, but may want to look into as they break new ground on inventive approaches to products and treatments previously determined to be unchangeable.
- InvestorPlace•2 months ago
Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today
The biopharmaceutical company, which is a clinical-stage company that develops medicines designed to treat addiction, said that it has retired all outstanding debt. Adial Pharmaceuticals said that the holder of the sole remaining, outstanding convertible note was able to fully convert the balance of the note into common shares of the company with the convertible note having a face value of $325,000 and was convertible into 162,500 shares of common stock. “As we position Adial for continued success in 2019, I am pleased to report that we have now completed the retirement of all outstanding debt instruments by facilitating the conversion of this note obligation,” Adial Pharmaceuticals CEO William Stilley said.
- ACCESSWIRE•2 months ago
4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018
CORAL GABLES, FL/ ACCESSWIRE / December 26,2018 / With 2019 just around the corner, the biotech industry is buzzing with excitement surrounding announcements of innovative treatment lotions and medical technologies designed to improve the quality of care for those suffering from all types of diseases and ailments. As companies work to develop new approaches to medical care which cater to both the needs and demands of consumers, the biotech industry may see significant market attention in the new year. Premier Health Group (PHGRF) (PHGI), Teladoc Health, Inc (TDOC), MINDBODY Inc (MB), and Adial Pharmaceuticals Inc (ADIL) are 4 biotech stocks representing companies working towards the future of their sector.
- ACCESSWIRE•2 months ago
Biotech News Driving These Companies
HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently. We are highlighting: Endonovo Therapeutics, ...
- GlobeNewswire•2 months ago
Adial Pharmaceuticals Retires All Outstanding Debt
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL;ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that the holder of the sole remaining, outstanding convertible note has fully converted the balance of the note into common shares of the Company. As previously reported, the convertible note had a face value of $325,000 and was convertible into 162,500 shares of common stock. William Stilley, CEO of Adial Pharmaceuticals, commented, “As we position Adial for continued success in 2019, I am pleased to report that we have now completed the retirement of all outstanding debt instruments by facilitating the conversion of this note obligation.
- ACCESSWIRE•2 months ago
Biotech Breakout Candidates
HENDERSON, NV / ACCESSWIRE / December 24, 2018 / It’s been a busy week for biotech, here are a few companies in the news you should start researching. Today we are highlighting: Delcath Systems, Inc. (DCTH), ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 20, 2018 /Biotech stocks Aduro BioTech and Adial Pharmaceuticals were both roaring on Wednesday on positive developments. Aduro BioTech, Inc. shares closed up nearly 20% yesterday on explosive trading volume compared to usual at around 7.2 million shares. The company announced earlier this week that it has entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly LLY to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / Biotech stocks Adial Pharmaceuticals and Cancer Genetics were exploding in Thursday’s session. Adial moved higher on news that the company is considering expanding AD04 to treat opioid use disorder. Shares of Cancer Genetics had no news to explain its dramatic share price jump.
- InvestorPlace•2 months ago
Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today
The news from Adial Pharmaceuticals (NASDAQ:ADIL) has to do with the company’s AD04 asset. This is a drug from the company that is used to treat individuals suffering from alcohol use disorder. The good news for ADIL stock is that the company is considering expanding the use of AD04.
- GlobeNewswire•2 months ago
Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl
ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced plans to expand activities around the Company’s lead asset, AD04, beyond alcohol use disorder (AUD), to now include its potential use in patients with opioid use disorder. According to the Centers for Disease control, in 2017 alone, more than 72,000 people in the US died of drug overdoses, at least two-thirds of which were linked to opioids.
- GlobeNewswire•2 months ago
Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder
ADILW) www.adialpharma.com a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Professor Hannu E.R. Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland was appointed as Coordinating Principal Investigator for the planned European Phase 3 clinical trial of AD04 for the treatment of Alcohol Use Disorder (AUD). This Phase 3 clinical trial will be a 24-week trial with 290 patients in 30 clinical sites in five European countries.
- ACCESSWIRE•2 months ago
Adial Pharmaceuticals, Analysts Coverage, Review and Target
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder "AUD" using its lead investigational new drug product, AD04. On November 29th, ADIL announced the formation of a Scientific Advisory Board. ADIL analysts coverage, review and target available here READ MORE.
- ACCESSWIRE•3 months ago
Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma
CORAL GABLES, FL / ACCESSWIRE / November 29, 2018 / The healthcare industry is evolving but isn't without its hurdles. While doctors and researchers work to find cures and solutions to both common and ...
- GlobeNewswire•3 months ago
Adial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder
ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
- GlobeNewswire•3 months ago
Adial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder
ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that company Chairman Bankole A. Johnson DSc, MD is being featured in a series of videos produced by The Doctor’s Channel, with the first video now available at this link. The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial expected to be run in 290 patients at 30 clinical sites across 5 European countries.
